# Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

> **NCT06011577** · PHASE3 · TERMINATED · sponsor: **Levomecor Inc.** · enrollment: 27 (actual)

## Conditions studied

- Major Depressive Disorder
- Depression

## Interventions

- **DRUG:** REL-1017
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06011577
- **Lead sponsor:** Levomecor Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-17
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Program Discontinued
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06011577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06011577, "Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06011577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*